Nilocap contains nilotinib, a targeted anti-cancer medicine used primarily in the treatment of certain types of leukemia. It belongs to a class of drugs known as tyrosine kinase inhibitors and is particularly effective in patients with chronic myeloid leukemia that is positive for the Philadelphia chromosome. It is an oral medication, designed for long-term management of cancer under specialist supervision.

Mechanism of Action:

Nilotinib works by specifically blocking the activity of BCR-ABL tyrosine kinase, a protein produced by abnormal fusion genes in cancer cells. This protein causes uncontrolled growth and multiplication of white blood cells in chronic myeloid leukemia. By inhibiting this enzyme:

• It stops the signal that tells cancer cells to grow

• Slows or stops the development of leukemia

• Helps restore the balance of normal blood cells in the body

  Uses:

  Nilocap is prescribed for:

  • Chronic myeloid leukemia (CML) in the chronic or accelerated phase

  • Especially in patients who are resistant or intolerant to first-line therapy such as imatinib

  • Sometimes used as a first-line treatment depending on clinical guidelines

    Adverse Effects:

    While effective, nilotinib can lead to some side effects, and regular monitoring is essential during treatment.

    Common side effects:

    • Headache

    • Nausea or vomiting

    • Diarrhea or constipation

    • Muscle and joint pain

    • Rash or skin itching

    • Tiredness and weakness